Archive for July 3rd, 2012

CHTP advised to conduct additional trial. OSUR FDA Approval. NVO terminates PCRX agreement. MNOV October FDA meeting.PTN raises cash + SPPI

Jul 03, 2012 No Comments by

Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) received advice from the FDA regarding further development of Northera (droxidopa) in the U.S. The FDA advised that the company conduct an additional trial to demonstrate that droxidopa has a significant and persistent effect’ on symptoms of neurogenic orthostatic hypotension. OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that the U.S. Food and Drug Administration […]

Daily News Read more